Gavreto (pralsetinib capsules - Blueprint Medicines) — Cigna

Initial criteria

• Patient age ≥ 12 years
• Patient has unresectable, recurrent, or metastatic disease
• Patient has rearranged during transfection (RET) fusion-positive or RET-mutation-positive disease
• The disease requires treatment with systemic therapy
• Patient has ONE of the following: (a) papillary or follicular thyroid carcinoma and the disease is radioactive iodine-refractory OR (b) oncocytic (formerly Hürthle cell) carcinoma

Approval duration

1 year